FDA Clears Updated Ezra Flash AI Software for MRI Scans
The updated AI-enabled software reportedly facilitates enhanced MRI imaging of the brain, abdomen, and pelvis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for updated artificial intelligence (AI) software that bolsters image quality on magnetic resonance imaging (MRI) scans.
Emphasizing noise reduction without sacrificing diagnostic integrity, the Ezra Flash AI software bolsters the quality of MRI scans of the brain, abdomen and pelvis, according to Ezra, the manufacturer of Ezra Flash AI.
In addition to enhanced neuroimaging, the newly FDA-cleared updates for the Ezra Flash AI software may provide visualization with abdominal and pelvic MRI scans, according to Ezra, the developer of the software. (Images courtesy of Ezra.)
The company maintained that the enhanced image quality obtained with Ezra Flash AI will provide greater clarity in MRI interpretation and precise analysis to facilitate a more timely diagnosis.
"The FDA clearance of Ezra Flash represents a significant advancement in making AI-powered cancer screening more accessible," said Daniel K. Sodickson, M.D., Ph.D, the chief scientific advisor at Ezra and chief of innovation in the Department of Radiology at the New York University Grossman School of Medicine. "This technology enables faster, more accurate early cancer detection, ultimately giving patients and their doctors clearer insights for making informed healthcare decisions."
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
